Solid Biosciences Inc. Form D Notices of Exempt Offering of Securities
Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.
- 2022-12-09: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2022-12-02; Total offering amount $9,200,000.
- 2020-10-26: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2020-10-22; Total offering amount $39,999,996.
| Filed | Federal exemption | Types of securities offered | Date of first sale | Total offering amount | Total amount sold | Total remaining to be sold | Investors who have already invested |
|---|
| 2022-12-09 | Rule 506(b) | Equity | 2022-12-02 | $9,200,000 | $9,200,000 | $0 | 13 |
|---|
| 2020-10-26 | Rule 506(b) | Equity | 2020-10-22 | $39,999,996 | $39,999,996 | $0 | 1 |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
|---|
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
|---|
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
|---|